Publication

The long road: improving outcome in elderly "unfit" AML?

Lowenberg, B. & Huls, G., 11-Jun-2020, In : Blood. 135, 24, p. 2114-2115 3 p.

Research output: Contribution to journalEditorialAcademicpeer-review

Copy link to clipboard

Documents

  • The long road improving outcome in elderly “unfit” AML

    Final publisher's version, 542 KB, PDF document

    Request copy

DOI

In this issue of Blood, Wei et al(1) report the results of a prospective randomized placebo-controlled trial that presents formal evidence of an overall survival benefit of adding venetoclax to low-dose cytarabine (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML) not considered eligible for intensive cytotoxic treatment.

Original languageEnglish
Pages (from-to)2114-2115
Number of pages3
JournalBlood
Volume135
Issue number24
Publication statusPublished - 11-Jun-2020

    Keywords

  • LOW-DOSE CYTARABINE, PLACEBO

ID: 128532076